To address this need, we conducted a systematic review and meta-analysis to evaluate and compare the efficacy of GLP-1 RAs in promoting weight loss and modulating body composition in individuals with overweight or obesity with or without T2DM
In 2009, the first compound demonstrating anti-obesity effects was reported, a dual agonist targeting both the GLP-1 receptor and the glucagon receptor [24]
Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isnt serious enough for treatment, said David A Ricks, chair and CEO of Eli Lilly, in a statement
Day 1 (First Use): Skin feels instantly smoother, softer, and refreshed